Top Story Today
Prostate Cancer Finally Gets Its Precision Oncology Moment
One in four men with newly metastatic prostate cancer has a broken gene called PTEN, and until now, there was nothing specifically designed to treat it. That changed when the FDA approved AstraZeneca's TRUQAP (capivasertib) as the first targeted therapy for PTEN-deficient hormone-sensitive prostate cancer. In the Phase 3 CAPItello-281 trial of over 1,000 men, adding TRUQAP to standard treatment extended progression-free survival by 7.5 months and cut the risk of worsening or death by 19%. Patients must test positive for PTEN loss via a new companion diagnostic before getting the drug, making this the first biomarker-gated treatment category in prostate cancer history.
Why it matters: This approval turns PTEN loss from a grim prognostic marker into a treatable target, establishing the same precision oncology playbook that transformed breast cancer with HER2 testing. Every newly diagnosed metastatic prostate cancer patient should now be tested, which means new infrastructure, new clinical workflows, and a philosophical shift in how doctors treat the most common male cancer.
Read more →Clinical Breakthroughs
Lilly Spent $2.3B on an Untested Drug. Seven Weeks Later, It Might Already Be Working.
About 70% of patients on Lilly's new JAK2 inhibitor (acquired via the Ajax Therapeutics deal) saw major spleen shrinkage in a 23-patient Phase 1 trial for myelofibrosis, a rare blood cancer. The drug works by locking JAK2 in its off position, a first-of-its-kind approach. Even more provocative: 35% of longer-treated patients saw their cancer-driving mutations cut in half, something existing JAK drugs almost never achieve. Zero dose-limiting toxicities so far.
Read more →Novartis's $12B RNA Bet Delivers Its First Real Report Card
For a disease with zero approved treatments, this is a big deal. Novartis's del-brax, an antibody-guided RNA drug inherited from the $12 billion Avidity acquisition, hit both primary and key secondary endpoints in a Phase 1/2 trial for FSHD muscular dystrophy. The drug reduced biomarkers of disease activity and muscle damage significantly versus placebo. Regulatory conversations are now underway, with accelerated approval potentially on the table.
Read more →J&J's Myeloma Combo Cut the Risk of Death by 53%
J&J's Talvey plus Darzalex combination slashed the risk of disease progression or death by up to 72% versus standard care in the Phase 3 MonumenTAL-3 trial for relapsed myeloma. At two years, 81% of patients on the combo were still progression-free. It's the first Phase 3 win for a GPRC5D bispecific in earlier-line myeloma, earning a plenary slot at EHA 2026.
Read more →The Obesity Drug Wars
Lilly's Triple Agonist Just Posted Weight Loss That Rivals Surgery
Retatrutide hit 30.3% body weight loss over two years in the Phase 3 TRIUMPH-1 trial, a number that puts it in bariatric surgery territory. The triple agonist (targeting GLP-1, GIP, and glucagon) also delivered a cardiovascular overhaul: triglycerides down 41%, blood pressure down 12 points. Pfizer's oral GLP-1 flamed out with 50%+ dropout rates, while Roche's dual agonist posted a solid but unspectacular 22.5%. The competitive hierarchy just crystallized.
Read more →The Obesity Drug That Doesn't Care About Your Scale
Survodutide won't win the weight-loss headline war at 16.6%, but its Phase 3 data revealed something different: visceral fat dropped 34%, liver fat plunged 63%, and lean muscle was largely preserved. In a separate liver disease trial, 84% of patients hit meaningful liver fat reduction versus 24% on placebo. Boehringer and Zealand are betting the real opportunity is the intersection of obesity and fatty liver disease.
Read more →Deals, IPOs, and Industry Shifts
Five Biotechs Raised $1.66 Billion in a Single Week
Parabilis Medicines shattered the record for largest venture-backed biotech IPO at $670 million, topping Kailera's $625 million raise from just two months earlier. Eikon ($381M), Veradermics ($256M), Agomab ($200M), and SpyGlass ($150M) rounded out a blockbuster stretch. Veradermics, which is developing an oral minoxidil pill for hair loss, popped 122% on day one. The median biotech IPO in 2026 has more than doubled versus 2025.
Read more →Incyte Quadrupled Its AI Drug Discovery Bet to $120M Upfront
After an initial $30 million pilot deal, Incyte expanded its Genesis Molecular AI partnership to $120 million upfront (cash plus equity) covering at least five new drug targets, with milestone payments exceeding $1 billion. The kicker: Incyte is now feeding its proprietary experimental data into Genesis's AI platform, betting the feedback loop will produce better drug candidates across oncology, hematology, and inflammation.
Read more →Illumina Cuts 300+ Jobs as Sequencing Competitors Close In
The genomics giant axed another 3.5% of its workforce, bringing total layoffs since 2022 to roughly 1,000. The real pressure: Ultima Genomics now offers $80 genomes (versus Illumina's $200), and Element Biosciences undercuts reagent prices by two-thirds. Revenue growth has stalled in the low single digits, and Illumina's era of comfortable pricing dominance looks definitively over.
Read more →